Immuneering Corporation announced on January 7, 2025, positive data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of IMM-1-104. The company reported an updated Overall Response Rate (ORR) of 43% and Disease Control Rate (DCR) of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. This compares favorably to the historic benchmark of 23% ORR and 48% DCR for gemcitabine/nab-paclitaxel alone.
Initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients showed target lesion shrinkage across all evaluable patients, including a 100% reduction, resulting in an ORR of 50% compared to a 32% historic benchmark for FOLFIRINOX alone. Additionally, initial data from the IMM-1-104 monotherapy arm in second-line pancreatic cancer demonstrated clear activity, including a partial response with a 67% target lesion reduction.
Based on these results, Immuneering plans to expand the Phase 2a trial to include three additional combination arms in 2025: IMM-1-104 with a BRAF inhibitor in BRAF-mutant melanoma, and IMM-1-104 with an immune checkpoint inhibitor in both melanoma and non-small cell lung cancer. The company also noted that IMM-1-104 continues to exhibit a highly differentiated safety profile, and planning for a potential pivotal clinical trial is underway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.